Certara, Inc. (NASDAQ: CERT) is a Healthcare company (Medical - Healthcare Information Services) with a market capitalization of $1.7B. The Maz Rating grades it against the other companies in its sector.
Certara, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $11.06, Certara, Inc. trades at 4.3x sales and 1.7x book value, with an EV/EBITDA of 18.0. Over the last twelve months it generated about $396M of revenue and a net loss of $63M. It runs a gross margin of 59.4%, an operating margin of 1.7% and a net margin of -16.1%. It shows return on equity of -6.4%, return on invested capital of 0.5% and a free cash flow yield of 3.5%. On the balance sheet: a debt-to-equity ratio of 0.30 and a current ratio of 2.58. Over the past 52 weeks the share price ranged from $4.45 to $12.61, with a beta of 1.30.
Certara, Inc. does not currently pay a dividend.
17 Wall Street analyst ratings cover the stock: 8 Buy and 9 Hold, for a Hold consensus. This is the sell side's view, separate from the Maz Rating.
Certara, Inc. provides advanced software solutions and technology-driven services, specializing in biosimulation throughout the entire drug development lifecycle. From initial drug discovery and preclinical research to clinical trials, regulatory submissions, and market entry, the company's core mission is to accelerate the delivery of new medicines to patients by transforming these processes with its innovative biosimulation software and expertise. Its extensive portfolio of technology-enabled services includes mechanistic and empirical biosimulation, strategic guidance for drug development and regulatory affairs, clinical pharmacology, model-based meta-analysis, specialized regulatory writing and medical communications, regulatory operations support, and market access consultation. Furthermore, Certara offers a robust suite of software platforms covering mechanistic and empirical PK/PD biosimulation, data standardization and compliance, scientific informatics, clinical outcomes databases for biosimulation, authoring and management of regulatory submissions, and market access communication. The company's clientele primarily comprises biopharmaceutical firms, academic institutions, and governmental organizations. Established in 2008 and headquartered in Princeton, New Jersey, Certara maintains a significant global presence, with operations spanning numerous countries including the United States, Canada, Spain, Luxembourg, Portugal, the United Kingdom, Germany, France, the Netherlands, Denmark, Switzerland, Italy, Poland, Japan, the Philippines, India, Australia, and China.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
Yes. As of September 2026, Certara, Inc. (CERT) is classified as HALAL by Maz Vantage: it passes all 5 published Shariah screening standards it was tested against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 20.0% / 30% · (Cash+Inv) / Mkt Cap (36m) 14.8% / 30% · Interest income / Revenue 1.37% / 5% | Pass |
| S&P Global | Debt / Mkt Cap (36m) 20.0% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 14.8% / 33% · Receivables / Mkt Cap (36m) 6.55% / 49% · Interest income / Revenue 1.37% / 5% | Pass |
| Dow Jones | Debt / Mkt Cap (24m) 20.0% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 14.8% / 33.33% · Receivables / Mkt Cap (24m) 6.55% / 33.33% · Interest income / Revenue 1.37% / 5% | Pass |
| MSCI | Debt / Avg Assets (4Q) 15.1% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 12.6% / 33.33% · Receivables / Avg Assets (4Q) 7.37% / 33.33% · Interest income / Revenue 1.37% / 5% | Pass |
| FTSE | Debt / Total Assets 20.6% / 33.33% · (Cash+ST Inv) / Total Assets 15.2% / 33.33% · (Cash+Recv) / Total Assets 21.9% / 33.33% · Interest income / Revenue 1.37% / 5% | Pass |
Yes. As of September 2026, Certara, Inc. (CERT) is classified as HALAL by Maz Vantage: it passes all 5 published Shariah screening standards it was tested against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
Yes. Certara, Inc. is within every AAOIFI limit: debt and interest-bearing cash and investments under 30% of its 36-month average market cap, and interest income under 5% of revenue.
About 1.37% of each dividend: Certara, Inc.'s interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.